Danaher to acquire Masimo for $9.9bn.

Danaher, a global life sciences and diagnostics innovator, agreed to acquire Masimo, a global medical innovator, for $9.9bn. "We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring. Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo. Importantly, becoming part of Danaher’s Diagnostics segment will strengthen our ability to scale our monitoring technologies globally and accelerate our mission of delivering Masimo innovations that empower clinicians to transform patient care," Katie Szyman, Masimo CEO.